Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Gurcha, Sudagar S ^a   Usha, Veeraraghavan ^a   Cox, Jonathan A G ^a   Fütterer, Klaus ^a   Abrahams, Katherine A ^a   Bhatt, Apoorva ^a   Alderwick, Luke J ^a   Reynolds, Robert C ^b   Loman, Nicholas J ^a   Nataraj, Vijayashankar ^a   Alemparte, Carlos ^c   Barros, David ^c   Lloyd, Adrian J ^d   Ballell, Lluis ^c   Hobrath, Judith V ^e   Besra, Gurdyal S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b University of Alabama at Birmingham   (United States)

^c GLAXOSMITHKLINE   (Spain)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; ANTIMYCOBACTERIAL AGENT; ASPARTATE TRANSFER RNA LIGASE; ASPARTYL TRANSFER RNA SYNTHETASE ASPS; BACTERIAL ENZYME; F 1673 0402; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEXOKINASE; UNCLASSIFIED DRUG; HYBRID PROTEIN; PIPERIDINE DERIVATIVE; PROTEIN BINDING; THIAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

AMINO ACID SUBSTITUTION; ARTICLE; ASPS GENE; BACTERIAL GENE; BACTERIUM MUTANT; BINDING SITE; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; IC50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NON SYNONYMOUS MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROCESS OPTIMIZATION; PROMOTER REGION; PROTEIN TERTIARY STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; WHOLE GENOME SEQUENCING; AMINO ACID SEQUENCE; BIOSYNTHESIS; CHEMISTRY; DIMERIZATION; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR CLONING; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; PATHOLOGY; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; TUBERCULOSIS, PULMONARY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANTITUBERCULAR AGENTS; ASPARTATE-TRNA LIGASE; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; THIAZOLES; TUBERCULOSIS, PULMONARY;

EID: 84915803426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113568     Document Type: Article

References (62)

1. Yew WW, Sotgiu G, Migliori GB (2012) Update in tuberculosis and nontuberculous mycobacterial disease 2010. Am J Respir Crit Care Med 184: 180-185.
2. Martinson NA, Hoffmann CJ, Chaisson RE (2011) Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc Am Thorac Soc 8: 288-293.
3. Dye C, Williams BG (2010) The population dynamics and control of tuberculosis. Science 328: 856-861.
4. Chiang CY, Centis R, Migliori GB (2010) Drug-resistant tuberculosis: past, present, future. Respirology 15: 413-432.
5. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C (2012) Totally drug-resistant tuberculosis in India. Clin Infect Dis 54: 579-581.
6. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K (2011) The challenge of new drug discovery for tuberculosis. Nature 469: 483-490.
7. Reynolds RC, Ananthan S, Faaleolea E, Hobrath JV, Kwong CD, et al. (2012) High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 92: 72-83.
8. Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb) 89: 354-363.
9. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 89: 334-353.
10. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, et al. (2012) Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol 7: 1377-1384.
11. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6(1): 29-40.
12. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, et al. (2007) Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 3: 323-324.
13. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
14. Matteelli A, Carvalho AC, Dooley KE, Kritski A (2010) TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 5: 849-858.
15. Palomino JC, Martin A (2013) TMC207 becomes bedaquiline, a new anti-TB drug Futur Mi robiol 8(9 1071 1080
16. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, et al. (2012) SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797-1809.
17. Sacksteder KA, Protopopova M, Barry CE, Andries K, Nacy CA (2012) Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 7: 823-837.
18. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, et al. (2012) MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 56: 324-331.
19. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, et al. (2012) Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 8: 334-341.
20. Christophe T, Jackson M, Jeon HK, Fenistein D, Contr eras-Dominguez M, et al. (2009) High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular anti-mycobacterial inhibitors. PLoS Pathog 5: e1000645.
21. Makarov V, Manina G, Mikusova K, Möllmann U, Ryabova O, et al (2009) Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324(5928): 801-4.
22. Wang F, Sambandan D, Halder R, Batt S, Weinrick B, et al (2013) Identification of a small molecule with activity against drug-resistant tuberculosis. Proc Natl Acad Sci USA 110(27): E2510-E2517.
23. Abrahams KA, Cox JA, Spivey VL, Loman NJ, Pallen MJ, (2012) Identification of novel imidazo[1, 2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One 7: e52951.
24. Pethe K, Bifani P, Jang J, Kang S, Park S, et al (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19, 1157-1160.
25. Goldman RC (2013) Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis 93: 569-588.
26. Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, et al. (2013) Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS ONE 8(9): e75245.
27. Guo M, Schimmel P (2012) Structural analyses clarify the complex control of mistranslation by tRNA synthetases. Curr Opin Struct Biol 22: 119-126.
28. Ling J, Reynolds N, Ibba M (2009) Aminoacyl-tRNA synthesis and translational quality control. Annu Rev Microbiol 63: 61-78.
29. Agarwal A, Nair SK (2012) Aminoacyl tRNA synthetases as targets for antibiotic development. Med Chem Commun 3: 887-898.
30. Paravisi S, Fumagalli G, Riva M, Morandi P, Morosi R, et al (2009) Kinetic and mechanistic characterization of Mycobacterium tuberculosis glutamyl-tRNA synthetase and determination of its oligomeric structure in solution. The FEBS Journal 276: 1398-1417.
31. Carter CW Jr (1993) Cognition. Mechanism and evolutionary relationships in aminoacyl-tRNA synthetases. Annu Rev Biochem 62: 715-748.
32. Kim SW, Lee EC, Choi C, Choi SY (2003) Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl Microbiol Biotechnol 61: 278-288.
33. Vondenhoff GH, Gadakh B, Severinov K, Van Aerschot A (2012) Microcin C and Albomycin analogues with aryl-tetrazole substituents as nucleobase isosters are selective inhibitors of bacterial aminoacyl tRNA synthetases but lack efficient uptake. Chem BioChem 13: 1959-1969.
34. Vondenhoff GH, Pugach K, Gadakh B, Carlier L, Rozenski J, et al. (2013) N-alkylated aminoacyl sulfamoyladenosines as potential inhibitors of aminoacyla-tion reactions and Microcin C analogues containing D amino acids. PLoS ONE 8(11): e79234.
35. Asp and inhibition of aminoacylation. The EMBO J 21(4): 760-768.
36. Vondenhoff GH, Van Aerschot A (2011). Aminoacyl tRNA synthetase inhibitors as potential antibiotics. Eur J Med Chem 46: 5227-5236.
37. Li H, Durbin R (2010) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595.
38. Li H, Handsaker B, Wyoker A, Fennell T, Ruan J, et al. (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25: 2078-2079.
39. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, et al (2012) VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22: 568-576.
40. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, et al (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6: 80-92.
41. Mahenthiralingam E (1998). Extraction of RNA from mycobacteria. Methods Mol Biol 101: 65-75.
42. Dietrich G, Schaible UE, Diehl KD, Mollenkopf H, Wiek S, et al (2000). Isolation of RNA from mycobacteria grown under in vitro and in vivo conditions. FEMS Microbiol Lett 186(2): 177-80.
43. Roy S (1983). A continuous spectrophotometric assay for Escherichia coli alanyl-transfer RNA synthetase. Anal Biochem 133: 292-295.
44. Lloyd AJ, Potter NJ, Fishwick CWG, Roper DI, Dowson CG (2013) Adenosine tetraphosphoadenosine drives a continuous ATP release assay for aminoacyl-tRNA synthetases and other adenylate forming enzymes. ACS Chem Biol 8: 2157-2163.
45. Lloyd AJ, Gilbey AM, Blewett AM, De Pascale G, Zoeiby AEI, et al. (2008) Characterisation of tRNA dependent peptide bond formation by MurM in the synthesis of Streptococcus pneumonia peptidoglycan. J Biol Chem 283: 6402-6417.
46. Kabsch W (2010). XDS. Acta Crystallogr D Biol Crystallogr 66: 125-131.
47. McCoy AJ, Grosse-Kunstieve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
48. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr Sect D 66: 486-501.
49. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum likelihood method. Acta Crystallogr Sect D 53: 240-255.
50. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49: 534-553.
51. Mitchell JE, Zheng D, Busby SJW, Minchin SD (2003) Identification and analysis of 'extended-10' promotors in Escherichia coli. Nucleic Acids Res 31: 4689-4695.
52. Vilchèze C, Jacobs WR Jr. (2007) The Mechanism of Isoniazid Killing: clarity through the scope of genetics. Annu Rev Microbiol 61: 35-50.
53. Ezgimen MD, Mueller NH, Teramoto T, Padmanabhan R (2009) Effects of detergents on the West Nile virus protease activity. Bioorg Med Chem 17: 3278-3282.
54. McGovern SL, Shoichet BK (2003) Kinase inhibitors: not just for kinases anymore. J Med Chem 46: 1478-1483.
55. Thorne N, Auld DS, Inglese J (2010) Apparent activity in high throughput screening: origins of compound dependent assay interference. Curr Opin Chem Biol 14: 315-324.
56. Shoichet BK (2006) Screening in a spirit haunted world. Drug Discov Today 13-14: 607-615.
57. Hopkins AL, Mason JS, Overington JP (2006) Can we rationally design promiscuous drugs? Curr Opin Struct Biol 16: 127-136.
58. Baell JB, Holloway GA (2010). New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J Med Chem 53: 2719-2740.
59. Baell J, Walters MA (2014). Chemical con artists foil drug discovery. Nature 513: 481-483.
60. Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK (2012). Recent developments and biological activities of thiazolidinone derivatives: a review. Bioorg Med Chem 20(11): 3378-95.
61. Eiler S, Dock-Bregeon AC, Moulinier L, Thierry JC, Moras D (1999). Synthesis of aspartyl tRNA (Asp) in Escherichia coli-a snap shot of the second step. EMBO J 18: 6532-6541.
62. Davis IW, Murray LW, Richardson JS, Richardson DC (2004). MOLPROB-ITY: structure validation and all atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res 32: W615-W619.